Breaking News: Business Strategy by Bristol-Myers Squibb and Pfizer Reduces Eliquis Price
Breaking Business News: Eliquis Price Reduction
In a groundbreaking move, Bristol-Myers Squibb Co. and Pfizer Inc. have joined forces to significantly lower the price of their blockbuster blood thinner, Eliquis. This decision is aimed at reducing the monthly cost from a staggering list price of $606 to just $346, marking a remarkable shift in the healthcare industry.
Details on Biotech and Pharmaceuticals
The strategy to bypass traditional middlemen highlights a growing trend in the pharmaceuticals sector, where companies seek to control pricing directly.
- Key Benefits: Patients will save substantially on a vital medication.
- Industry Implications: This could set a precedent for other biotech and pharmaceutical companies.
Political Context: Trump's Influence
This move may also resonate within the political landscape, especially considering Donald Trump's recent statements regarding business practices in the United States.
Conclusion: Impacts on Business News
Stay tuned for further updates as this story develops, highlighting critical interactions within the healthcare and biotechnology sectors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.